Eris Lifesciences Limited has released the transcript of its analyst and investor call, providing transparency into management’s commentary on financial performance for the quarter ended June 30, 2026. The call was held on August 4, 2026, immediately following the announcement of the company’s quarterly results. This disclosure ensures that all investors and market participants have equal access to the detailed discussions regarding operational updates and financial outcomes for Q1FY27.

The filing, submitted to both the Bombay Stock Exchange and the National Stock Exchange of India Limited, serves as a formal notification of the transcript’s availability. Milind Talegaonkar, Company Secretary and Compliance Officer of Eris Lifesciences, signed the communication, confirming that the document is hosted on the corporate website under the financials section. The file is specifically named "Q1 FY27 Earnings Call Transcript" for easy retrieval by stakeholders.

Disclosure Details

The primary purpose of this submission is to inform the exchanges and the investing public about the location of the earnings call record. The company emphasized that the transcript is available at https://eris.co.in/financials/ . This step aligns with regulatory requirements for timely dissemination of material information following quarterly result announcements.

Regulatory Compliance

The notification was addressed to the BSE Limited at Phiroze Jeejeebhoy Towers, Mumbai, and the National Stock Exchange of India Limited at Bandra Kurla Complex, Mumbai. By making the transcript publicly accessible on its website, Eris Lifesciences complies with listing regulations that mandate fair disclosure of information shared with analysts and institutional investors. The filing does not contain new financial data but rather directs readers to the comprehensive account of management’s views on the recent quarter.

Investors seeking insights into the drivers behind the Q1FY27 results are advised to review the full transcript on the company’s portal. The availability of this document supports informed decision-making by providing context to the numerical figures reported in the standalone financial results.

Eris Lifesciences will host a virtual one-on-one analyst meet with Bandhan Mutual Fund on Tuesday, Aug 04, 2026, at 4:00 PM IST. The interaction aims to provide institutional investors with an update on the company’s operations using only publicly available information, ensuring no unpublished price-sensitive information (UPSI) is disclosed. This engagement reflects the company’s ongoing commitment to transparency under SEBI’s disclosure norms.

The meeting was scheduled pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Management representative Mr. Krishnakumar Vaidyanathan will lead the discussion. The schedule is indicative and remains subject to change due to unforeseen developments. The company confirmed that discussions will be strictly limited to data already in the public domain.

Meeting Details

The following table outlines the specific parameters of the scheduled investor interaction:

Compliance Framework

The intimation was issued by Milind Talegaonkar, Company Secretary & Compliance Officer of Eris Lifesciences Limited, on July 30, 2026. The notice was submitted to both the BSE Limited and the National Stock Exchange of India Limited. By restricting the dialogue to publicly available documents, the company ensures adherence to regulatory standards regarding insider trading and information symmetry.

What This Means for Investors

This scheduled interaction allows Bandhan Mutual Fund to engage directly with management regarding operational metrics and strategic updates already disclosed in public filings. For broader market participants, such meetings signal active investor relations activity, though no new financial figures or strategic shifts were announced in this specific notice. Investors should monitor subsequent filings for any material developments discussed during these sessions.